CuraGen is a biotechnology company pioneering the systematic
application of genomics to accelerate the discovery & development
of therapeutic and agricultural products.
Of all of the biotechnology sub-disciplines in terms of return on
investment, genomics is purported to have one, if not the highest
potential. In layman's language, CuraGen thinks they can speed up
the tedious, therefore expensive, processes of finding genes which
code for proteins involved in disease processes. They claim they
have developed automated, "high-throughput" means of also
discovering chemicals which can interact with these proteins,
thereby altering a disease process. They propose to computerize
the whole, complicated database, and make money by charging
subscription fees, by engaging in research collaborations, and by
retaining product rights for revenues and royalties. |
